Granulocyte-colony-stimulating-factor use in decompensated cirrhosis: lack of survival benefit and probable predisposition to hepatocellular carcinoma

ConclusionSurvival in DC was shorter than what was expected in the natural history of the disease after GCSF use.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research